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ABSTRACT 
This paper presents the first European appropriateness criteria for the use of cardiovascular imaging in 
heart failure, derived from voting of the European national Imaging Societies representatives. The paper 
describes the development process and discusses the results. 
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INTRODUCTION 
The European Association of Cardiovascular Imaging (EACVI) has recognised the need for the 
development of appropriateness criteria for the use of cardiovascular imaging (CVI) in clinical practice in 
Europe and have published a statement in this regard1. The evolving role of CVI in heart failure (HF) due 
to diversification of indications and to the rise in HF prevalence, partially due to better life expectancy and 
higher HF prevalence in the elderly2,3,4 has driven the EACVI to commence with the development of 
appropriateness criteria for the use of CVI in HF. 
METHODS 
Development process 
The process began with a review of the literature regarding the use of CVI in HF performed and reported 
in the European Heart Journal of Cardiovascular Imaging by the Expert Panel, which includes members of 
the Imaging Taskforce and invited authors, including one invited member of the ESC HF Association2. The 
aim of this document was to inform the process of definition of clinical indications for the use of CVI in HF 
and the process of scoring of appropriateness for each modality in each indication. The literature review 
was structured according to common HF clinical scenarios.  
The next step, performed by members of the Expert Panel and of the Appropriateness Criteria 
Development Team, was the definition of clinical indications for the use of CVI in each HF clinical scenario 
and the development of scoring tables. The scoring tables, instructions and copies of the EACVI 
appropriateness criteria development need statement and of the published report of literature review 
were sent to the Voting Panel members for the first round of scoring. The instructions briefly explained 
the process already extensively detailed in the statement paper. Our appropriateness criteria 
development process was the first to offer the voters a literature review purposely written by the Expert 
Panel and published prior to commencement of the voting process.   
The Voting Panel members were individuals recommended as representatives by the European National 
Imaging Societies and Working Groups collaborating with the EACVI when the process began (April 2014). 
The Voting Panel covered all geographic areas of Europe and the range of European realities regarding 
healthcare systems, needs and availabilities. 
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Statistical analysis of the first round of scores and feedback from the Voting Panel members regarding the 
scoring tables and the clarity of the questionnaire revealed the need for simplification of the scoring 
tables to eliminate repetitions and unnecessary expansions together with the need for improvement of 
the questionnaire to eliminate ambiguities. Following the face-to-face meeting with the Voting Panel 
members (appendix), a second round of scoring was performed using the optimised scoring tables.  
Transparency and the inclusive nature of the process were ensured by interaction with the National 
Societies’ representatives at the EACVI Summit in June 2015. The Consensus Meeting organised at the ESC 
Congress in August 2015 made the development process more robust, supporting the final interpretation 
of results by the Appropriateness Criteria Development Team.   
Clinical scenarios and clinical indications 
The common HF clinical scenarios are diagnosis, treatment planning and follow-up, each of them having 
two distinct sub-scenarios, as shown in Figure 1. The clinical scenarios were defined based on the clinical 
experience of the Expert Panel, on the ESC guidelines for the diagnosis and treatment of acute and 
chronic HF5 and on the literature review. Clinical indications for the use of CVI in each HF clinical scenario 
and sub-scenario are detailed in Figures 2, 3, 4 and 5. They represent common clinical scenarios seen in 
contemporary practice, but do not include every conceivable clinical situation. Thus, some patients seen 
in clinical practice are not represented in this document or have additional extenuating features 
compared with the clinical scenarios presented. 
Analysis of the scores 
The appropriateness criteria were developed using the RAND-UCLA method, a two-round modified Delphi 
exercise6. Ratings of 1–3 were classified as inappropriate, with a rating of one indicating the greatest 
degree of inappropriateness. Ratings of 7–9 were classified as appropriate, with a rating of nine indicating 
the greatest degree of appropriateness. Ratings of 4–6 were classified as uncertain, being neither 
appropriate nor inappropriate. Scores in the “uncertain” category resulted mainly from the scoring of the 
use of a modality for a certain clinical indication in the appropriate range by some voters and lower by 
other voters. High scores were given by voters already using or still using that modality for the given 
clinical indication, whilst low scores were given by voters not yet using or no longer using the modality for 
that clinical indication.   
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Upon return of the scoring tables from voters, the scores were tabulated and statistical analyses were 
performed to calculate the median numerical score for each indication. The level of agreement among 
voting panel members was subsequently determined. Agreement was based on four or fewer panellists 
rating outside the three-point region containing the median (1–3; 4–6; 7–9), and disagreement was based 
on five or more panellists rating in each extreme (1–3 and 7–9), as per the RAND/UCLA protocol for a 15-
member panel. The ratings from each panellist had equal weight in producing the final result for the 
indications. 
The characterisation of the use of a certain CVI modality for a certain clinical indication as appropriate (A), 
inappropriate (I) or of unknown appropriateness (U) as described in the appropriateness criteria 
development methodology, reduced the differences in between modalities and indications observed in 
the initial scores. The characterisation was made when the median score value was in the 3 point range 
category (A for 7-9, U for 4-6, I for 1-3). The characterisation U is also classically attributed when there is 
disagreement in between voting panel members, despite the median score falling within one of the two 
other categories.  
The heterogeneous European reality, with differences in current clinical practice7 reflected in scoring, had 
a major impact in the final results despite the action taken to help resolve disagreement. In the case of 
some modalities and some clinical indications, the disagreement was favourable, bringing up the 
characterisation from I to U and encouraging future acquisition of further evidence in this regard. In the 
case of other modalities and clinical indications, the disagreement was unfavourable, bringing down the 
characterisation from A to U; however, the characterisation U does not discourage clinical use following 
locally established patterns, it only again encourages the acquisition of further evidence. 
Analysis of the results to identify the outlier voters generating the most disagreement, found them to 
belong to the most developed countries and to the medical societies owning the larger volume of 
advanced technology for the longer period of time. These medical societies have been at the centre of 
research regarding clinical implementation of modern techniques and technologies and they have the 
higher density of opinion leaders in the field. We found that, despite creating disagreement, the outliers 
actually raised the median score regarding the use of modern techniques in the majority of clinical 
indications.  
Given the higher perceived likelihood of disagreement in the context of heterogeneous European reality, 
the Appropriateness Criteria Development Team decided to present the results based on the median 
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score range which, regardless of this heterogeneity, may reflect more directly the opinion of the voting 
panel; the existence of disagreement is highlighted by an associated “d”. The reader is invited to consider 
the result with an associated “d” as a “U” within the current heterogeneous European context, bearing in 
mind though that in a more homogeneous context there may have been no disagreement. Despite this 
attempt to rationalise the results, there are situations in which similar clinical indications were scored 
differently for the same imaging modality. One example is that of cardiac magnetic resonance (CMR) for 
non-urgent (delayed) assessment for first diagnosis of HF, which scored within “A” range with or without 
a “d” depending on whether the initial symptomatic presentation was as an emergency or elective, which 
should make no difference in this case. 
SCENARIOS AND CVI INDICATIONS 
The appropriateness criteria for the use of CVI in HF are displayed in tables 1-5. Tables 1-4 present a 
detailed description of the appropriate use of CVI in HF per clinical indication, to support decision-making 
in clinical practice, taking into consideration further diversification of clinical scenarios for a particular 
patient, availability, coexistent situation influencing the decision (for example implanted non-CMR 
compatible device excludes CMR) or the choice of invasive coronary angiography instead of non-invasive 
CVI in the assessment of HF aetiology. Table 5 shows a summary of the appropriate use of CVI in a HF 
patient broadly, per clinical scenario, without considering sub-scenarios, by combining the clinical 
indications and keeping the higher reached score. This approach justifies the need for availability of a 
certain CVI modality. For example, whilst stress echocardiography is inappropriate for the urgent first 
diagnosis of HF in the symptomatic patient with emergency presentation, it is appropriate in the diagnosis 
of HF aetiology, so, it is appropriate for use in HF.  
CVI use in the first diagnosis of HF 
HF is a syndrome consisting of symptoms and signs resulting from an abnormality of cardiac structure 
and/or function2, 5. The symptoms are non-specific and the signs can be absent in patients receiving 
treatment, so the demonstration of an abnormality of cardiac structure and/or function is essential for HF 
diagnosis2, 5. Non-invasive CVI is used in the first diagnosis of HF to detect abnormalities of cardiac 
structure and/or function, which can explain the symptoms and signs5. The first diagnosis can be made in 
symptomatic patients presenting as an emergency for hospital admission or presenting electively as 
outpatients. It can also be made in asymptomatic patients, without heart failure, as an incidental finding 
during assessment performed for a different reason. Echocardiography is the CVI modality usually 
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underpinning the first diagnosis of HF in urgent, elective or screening settings. As seen from their final 
scores, the multinational European voting panel members agreed that the use of the available CVI 
modalities could differ in these settings, because of practicalities.  
Together with bedside portability, wide availability of both equipment and expertise is needed for 
modalities used in urgent cases. The expertise has to be available day and night on-call to cover such an 
application. Echocardiography has all the needed characteristics and had unanimous maximal scoring. It 
was also unanimously agreed that there is no role in these settings for stress echocardiography, 
radionuclide angiography (RNA), single-photon emission computed tomography (SPECT) and positron 
emission tomography (PET). Cardiac magnetic resonance (CMR) and cardiovascular computed 
tomography (CT) scored within the “I” range; however, the opinion of some voters that there may be a 
role for these methods in the acute settings of the emergency department created disagreement, 
highlighting a potential future role of “on-call” for these modalities.  
When not urgent, the ability to offer a certain CVI modality before discharge or in a “one-stop” basis in 
outpatient clinics, depends on availability of resources; the clinical indications we defined account for this 
practical reality, and the results differed for the two types of priority (urgent and non-urgent or delayed 
assessment). CT scored in the “U” range, whilst CMR scored within the “A” range for delayed first 
diagnosis of HF. The disagreement in regard with CMR use in delayed first diagnosis of HF in patients 
presenting as an emergency seems to originate from pure misunderstanding, because the delayed use 
should not depend upon the type of initial presentation. The same should be the case for the use of 
SPECT and PET in these settings.  
There are situations in which the use of a modality is inappropriate in acute settings because of the 
potential complications, as for example the use of stress echocardiography in the urgent assessment of 
the patient presenting with HF symptoms, and this indication scored in the “I” range. However, as already 
mentioned in the general description of the results section, there is a role for stress echocardiography in 
the delayed assessment of patients presenting with HF. 
Asymptomatic patients may be found during screening or assessment for other reasons, usually with 
echocardiography, to have abnormalities which could lead to HF. Cardiomyopathy screening may need 
CMR, which scored U in these settings of screening cardiomyopathy patients for heart failure, rather than 
screening for cardiomyopathy. Baseline and periodic screening of systolic function is performed in 
patients on cardiotoxic chemotherapy, usually with echocardiography. However, in case of poor 
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echocardiography window or uncertain results, CMR is essential; furthermore, in the absence of CMR or 
sometimes in the absence of high-resolution echocardiography with contrast, if needed, RNA could be 
used. This reality is reflected in the results. Considerations regarding contrast echocardiography, as well 
as all other echocardiography techniques are included under “echocardiography”. Asymptomatic patients 
with diabetes are offered left ventricular systolic function screening with echocardiography (A) or CMR in 
cases with poor echocardiography window (U); the voting panel took into consideration coronary disease 
screening in these patients too, scoring U for the relevant tests (stress echo, CMR, CT, SPECT).  
The case of the patient with cardiac history of myocardial infarction, coronary artery disease or structural 
heart disease was separately and extensively considered, because of inherent particularities. For example, 
the ESC HF guidelines5 recommend direct referral for echocardiography, without a natriuretic peptide 
assessment in patients with history of myocardial infarction and presentation with suspected HF, because 
of high pre-test likelihood of HF in these patients.   
The patient with myocardial infarction and HF may represent a more stringent emergency, if urgent 
revascularisation is needed with or without treatment of potential mechanical complications5. 
Consequently, both non-invasive and invasive CVI should be provided with priority. In some situations, 
even CMR may be more likely needed as an urgent test, in preparation for surgery, and this was 
recognised by the voting panel by scoring CMR in the U rather than I range for this indication. The ESC HF 
guidelines5 recommend coronary angiography in case of heart failure and coexistent coronary disease. 
Urgent invasive coronary angiography may be needed in case of acute presentation with heart failure and 
acute coronary syndrome. In patients with history of myocardial infarction or known coronary artery 
disease, in the absence of an acute coronary syndrome at the time of presentation, CT coronary 
angiography rather than invasive coronary angiography is increasingly used. Consequently, the 
assessment of existence of inducible ischaemia as reason for HF is often performed following coronary 
angiography when uncertainty regarding the functional severity of coronary disease persists. Similarly, 
the assessment of existence of viability in this patient category is performed in knowledge of coronary 
anatomy, to plan revascularisation. In the above-described circumstances, all relevant methods scored 
highly appropriate. Stress echocardiography refers both to pharmaceutical stress and exercise; the role of 
stress echo in HF of ischaemic aetiology comprises exercise echocardiography to detect dynamic mitral 
regurgitation and assess mitral regurgitation severity.  
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The patient with history of valve disease has first diagnosis of HF made by echocardiography and all other 
tests scored inappropriate in urgent settings, with some disagreement in the case of CMR. As a delayed 
test, stress echocardiography was scored as appropriate; this is obviously true in case the severity of 
valvular disease at rest does not explain HF symptoms and can be used to re-evaluate the severity of 
valve disease based on stress findings or to detect ischaemia. As a delayed test, CMR scored appropriate 
with some disagreement. CT scored U, given the emerging evidence regarding the role of calcium scoring 
in the assessment of aortic stenosis severity.  
The patient with a history of congenital heart disease often benefits from CMR or CT for diagnosis, and 
this is mirrored in the results.   
CVI use for diagnosis of HF aetiology 
The diagnosis of HF aetiology may be made concomitantly with the first diagnosis of HF or subsequently, 
based on a separate second test. 
The diagnosis of ischaemic aetiology can be suggested by invasive coronary angiography combined with 
fractional flow assessment (FFR) when needed, particularly in cases presenting with HF and acute 
coronary syndrome, in cases with a history of myocardial infarction, in cases with history of coronary 
disease without myocardial infarction or in cases with multiple risk factors for coronary artery disease and 
left ventricular systolic dysfunction with regional wall motion abnormalities typical for ischaemic heart 
disease. Coronary artery disease resulting in HF is more likely to be severe, extensive, proximal disease, 
which could involve the left main stem or all three coronary vessels. Consequently, induced ischaemia 
during a functional imaging study is likely to be extensive and potentially associated with complications at 
a higher than average incidence. Caution is required particularly for dobutamine stress echocardiography, 
especially in case of severe left ventricular systolic dysfunction at rest and/or in case of an already existing 
extensive scar of myocardial infarction. The risk is smaller for a vasodilator drug based functional imaging 
test. Stress echocardiography, CMR or SPECT based functional studies were all scored as appropriate. 
There was some disagreement for SPECT, mirroring the known possibility of a negative test in case of 
balanced ischaemia in patients with three-vessel coronary artery disease, however, balanced ischaemia 
has been previously demonstrated to be rare8. There was also disagreement in regard to appropriateness 
of stress echocardiography in patients already having had a coronary angiogram. This is because in such 
cases the test is rarely needed to assess ischaemia and consequently diagnose ischaemic aetiology of HF, 
but rather to assess viability. Currently, in clinical practice fractional flow reserve is used when necessary 
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to determine the significance of coronary artery lesions in HF patients, avoiding the risk of high dose 
dobutamine stress echocardiography in these patients. Furthermore, the stress echocardiography score 
was lower (7) in case of existence of regional wall motion abnormalities at rest typical for ischaemic 
aetiology (scar of myocardial infarction), acknowledging the relatively higher risk of the test in these 
settings. CT coronary angiography can be used to assess existence of coronary artery disease in HF 
patients; the test scored A with some disagreement in the patient with normal echocardiographic 
findings, and it scored U in case of systolic dysfunction with regional wall motion abnormalities at rest, if 
an invasive coronary angiogram was not already performed. We have to highlight that CT coronary 
angiography has to be performed at a heart rate of less than 65 beats per minute and beta-blockers are 
administrated prior to the test to immediately lower the heart rate if needed; this may be poorly 
tolerated by patients with decompensated HF, in need of gradual optimisation of treatment. Despite 
limited availability, there is an established role for PET in the diagnosis of ischaemic aetiology and this is 
reflected in the “U” score and even “A” score with some disagreement following coronary angiography. 
The diagnosis of non-ischaemic aetiology was the subject of separate extensive consideration and scoring. 
In the case of valve disease with severity (diagnosed with echocardiography) explaining the symptoms, 
further tests scored “I”, with some disagreement in regard with stress echocardiography and CMR 
thought by some voters to have potential added value. Stress echocardiography and CMR scored “A” in 
case the valve disease severity does not explain the symptoms; all other tests scored “I” in this case. 
However, there was some disagreement regarding CT and PET, thought by some voters to play a role in 
this case. In the opinion of this writing group, CT coronary angiography is very good for exclusion of 
coronary artery disease in valve disease patients, however, the immediate lowering of heart rate for the 
test described above may be poorly tolerated by valve disease patients presenting with HF. 
CMR and, with some disagreement, cardiac CT scored “A” in the assessment of HF patients with cardiac 
tumour, pericardial disease or congenital heart disease on an initial echocardiogram. PET scored “U” for 
further diagnosis of cardiac tumour and stress echocardiography scored “U” in the case of congenital 
heart disease, reflecting evolving roles for these modalities in the above-mentioned indications. The 
opinion of this writing group is that PET plays an important role in the assessment of cardiac tumours, and 
the score “U” rather than “A” should mirror the limited availability of this test around Europe. 
The diagnosis of diastolic dysfunction as a reason for HF is extremely important, because of the increasing 
prevalence of HF with preserved left ventricular ejection fraction, which represents about 50% of the HF 
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population2, 9. The diagnosis is made primarily by echocardiography (“A”), with an evolving role for stress 
echocardiography in the borderline cases based on echo at rest (“U”) and for CMR (“U”). The diagnosis of 
diastolic dysfunction aetiology can benefit from CMR (“A”) to diagnose hypertrophy and infiltration. The 
use of cardiac CT for assessment for diastolic function is complex and currently not realistic for routine 
clinical use, explaining the “I” score. In regard with diagnosis of diastolic dysfunction aetiology, recent 
applications of CT and SPECT to diagnose amyloidosis could justify the “U” and “Id” scores instead of “I”.  
 
CVI use for HF treatment planning 
All non-invasive CVI modalities may play a role in HF treatment planning.  
For revascularisation planning, echocardiography scored “A” for all indications, except for the assessment 
of inducible ischaemia. There was a disagreement in regard with the role of echocardiography at rest to 
diagnose viability, given the fact that echocardiography suffices for this diagnosis only in case of existence 
of at least partially preserved contractility and myocardial thickness in the segments assessed. Stress 
echocardiography scored “A” for viability and inducible ischaemia assessment; caution is however 
particularly required in the case of assessment of inducible ischaemia, which implies administration of 
high dose dobutamine. CMR scored “A” for all revascularisation related clinical indications, with or 
without aneurysmectomy. Continuing to be used in some centres for volumes and systolic function 
assessment, RNA scored “U”. SPECT scored “A” for inducible ischaemia and viability assessment. CT 
scored “A” with some disagreement for preoperative assessment before aneurysmectomy. PET scored 
“A” for viability assessment and, with some disagreement, for assessment of inducible ischaemia as well; 
the disagreement should be again explained by the limited availability of PET around Europe, rather than 
by the value of the test, because PET has excellent diagnostic value for detection of ischaemia and, 
furthermore, it is the only technique providing true quantitative assessment.  
For ICD planning, echocardiography and CMR scored “A” for LV systolic function assessment and 
echocardiography (with some disagreement reflecting the need for further testing in case of lack of 
diagnostic findings), stress echocardiography, CMR and SPECT scored “A” for diagnosis of ischaemic 
aetiology. CT and PET scored “U” for diagnosis of ischaemic aetiology. However, it is highly likely that a 
patient for whom ICD implantation is planned will have invasive coronary angiography performed for 
diagnosis of ischaemic aetiology of HF, rather than non-invasive CVI.  
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For CRT planning, echocardiography and CMR scored “A” because they provide a complete 
comprehensive cardiac assessment (echocardiography), LV systolic function assessment, LV lead 
placement guiding and assessment of the right ventricle (echocardiography and CMR). Whilst stress 
echocardiography scored “I”, there was disagreement from voters aware of the role stress 
echocardiography played in the assessment of viability of the postero-lateral wall, which is paced by the 
pacemaker LV lead for CRT. All other modalities scored “U”, given their role in the assessment of LV 
systolic function (RNA, SPECT), viability (SPECT, PET) or visualisation of the cardiac veins (CT).  
For LVAD planning, echocardiography scored “A”, providing a complete cardiac assessment together with 
the assessment of LV systolic function. Accurate LV systolic function evaluation can be also performed 
with CMR (Ad) or RNA (U).  
CVI use for HF follow-up 
The planned follow-up of HF patients should be based primarily on echocardiographic assessment (“A”) 
with all other imaging modalities playing a role in further assessment, when necessary, because of 
echocardiographic findings in need of elucidation. In clinical practice, further assessment using alternative 
modalities is rarely needed during follow-up, because usually a complete diagnosis is already available at 
this stage. The main exception is the case of patients with poor echocardiographic window, in which the 
planned follow-up may have to be based on CMR or RNA. 
The planned follow-up of CRT is usually based on echocardiography, which scored “A”.  
In case of new symptoms, the HF patient will be initially assessed with echocardiography (“A”). However, 
all CVI modalities play a role in further assessment if this becomes necessary as a result of initial 
echocardiography. CMR scored “A” for further assessment; with some disagreement, stress 
echocardiography scored “A” too, mainly as a result of the evolving role of exercise echocardiography in 
the assessment of the HF patient. All other modalities scored “U”, acknowledging that their role depends 
on patient or service particularities. For example, in case of poor echocardiographic window and in the 
absence of available CMR, RNA can be used for assessing LV systolic function. 
CLINICAL IMPLICATIONS 
As highlighted in the present report, non-invasive CVI plays an important role in patients with HF, with all 
types of modalities being used according to the mode of presentation, for the diagnosis, treatment 
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planning and follow-up. This document provides a framework for decisions regarding judicious utilisation 
of imaging in the management of patients with HF seen in clinical practice. However, the reported data 
also reflect practice heterogeneity across Europe, with broad variations in access to modern technology 
and imaging facilities, educational platform, training requirements, certification guidelines, and 
reimbursement systems.  
 
Unlike guidelines, which are solely based on scientific evidence, the present appropriateness criteria are 
thus also based on socio-economic considerations influencing the clinical practice of the voting panel 
members, as reflected in their scores. Hence, the present criteria are intended to provide guidance for 
patients and clinicians, but are not intended to diminish the acknowledged difficulty or uncertainty of 
clinical decision-making and cannot act as substitutes for sound clinical judgment and practice 
experience. This means that whilst a certain CVI modality may be inappropriate for a certain clinical 
indication in principle, it may still be appropriate for use in certain circumstances. 
 
Also, the present appropriateness criteria do not pertain to non-European communities and can be 
somewhat different to those published by the American Society of the American College of Radiology and 
the American College of Cardiology Foundation10, which derived from a more homogeneous society, with 
similar clinical practice and access to modern technology between voting panel members. 
 
Finally, the writing group also acknowledges that HF represents a rapidly evolving field with increasing 
evidence for effective therapies and diagnostic tests, and therefore anticipates that this document should 
be updated in a timely fashion.  
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Figure 1: Clinical scenarios in which cardiovascular imaging is used in heart failure 
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Figure 2: Clinical indications for cardiovascular imaging use for first diagnosis of heart failure  
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Figure 3: Clinical indications for cardiovascular imaging use to diagnose the aetiology of heart 
failure
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Figure 4: Clinical indications for cardiovascular imaging use for heart failure treatment planning 
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Figure 5: Clinical indications for cardiovascular imaging use in heart failure follow-up 
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  Table 1: Appropriateness criteria for the use of CVI in the first diagnosis of HF to detect abnormalities of cardiac  
  structure and/or function, which could explain symptoms and signs 
Clinical indications 
Cardiovascular imaging modalities 
Echo 
Stress 
Echo 
CMR RNA SPECT CT PET 
Symptomatic 
patients 
with emergency 
presentation 
Urgent assessment A I Id I I Id I 
Non-urgent assessment A U Ad I Id U Id 
with  elective 
presentation  
Urgent assessment A I Id I I Id I 
Non-urgent assessment  A U A Id U U U 
Asymptomatic 
patients 
Cardiomyopathy screening A I U I I I I 
On cardiotoxic 
chemotherapy 
Initial screening A I Ad U I I I 
Periodical screening A I U U I I I 
Screening of patient with diabetes A U U Id U U Id 
Patients with 
a cardiac 
history  
History of 
myocardial 
infarction or 
known CAD 
 
 
First LV 
systolic 
function 
assessment 
Urgent 
assessment 
A I U I I I I 
Delayed 
assessment 
A Id Ad Id U I Id 
LV systolic function 
assessment for ICD 
A Id A U U Id Id 
Assessment of inducible 
ischaemia 
Id A A Id A Id Ad 
Assessment of viability U A A I Ad I A 
History of 
structural 
heart disease 
Valve 
disease  
Urgent 
assessment 
A I Id I I I I 
Non-urgent 
assessment 
A A Ad Id I U I 
Congenital heart disease A Id A I I U I 
 
A: appropriate, d: existence of disagreement in scores, I: inappropriate, ICD: Implantable Cardioverter 
Defibrillator, LV: left ventricle, U unknown appropriateness 
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  Table 2: Appropriateness criteria for the use of CVI for diagnosis of HF aetiology 
Clinical indications 
Cardiovascular imaging modalities 
Echo 
Stress 
Echo 
CMR RNA SPECT CT PET 
Diagnosis of 
ischaemic 
aetiology 
HF with normal findings on echocardiogram - A A Id Ad Ad U 
HF with regional wall motion abnormalities 
(RWMA) typical for ischaemic aetiology 
- A A I Ad U U 
HF with RWMA not 
typical for ischaemic 
aetiology 
Before coronary 
angiogram 
- A A I Ad U U 
After coronary 
angiogram 
- Ad A I Ad Id Ad 
Viability 
assessment 
Before coronary angiogram Ad A A I Ad I Ad 
After coronary angiogram U A A I Ad I Ad 
Diagnosis of 
non-
ischaemic 
aetiology   
Valve disease 
on initial echo 
Valve disease severity 
explains HF symptoms 
- Id Id I I I I 
Valve disease severity does 
not explain HF symptoms 
- A A I I Id Id 
Cardiac tumour on initial echo - I A I I Ad U 
Pericardial disease on initial echo - I A I I A Id 
Congenital heart disease on initial echo - U A I I Ad I 
Diagnosis of 
diastolic 
dysfunction as 
HF aetiology  
Diagnosis of diastolic 
dysfunction 
A U U I I I I 
Diagnosis of diastolic 
dysfunction aetiology 
A U A I Id U I 
 
  Abbreviations: see above 
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Table 3: Appropriateness criteria for the use of CVIin HF treatment planning clinical indications 
Clinical indications 
Cardiovascular imaging modalities 
Echo 
Stress 
Echo 
CMR RNA SPECT CT PET 
Revascularisation 
LV volumes and systolic function assessment A Id A U U U Id 
Assessment of viability and MR Ad A A I A I A 
Assessment of inducible ischaemia and MR Id A A I A I Ad 
LV-aneurysmectomy A Id A I Id Ad U 
Device planning   
ICD planning 
LV systolic function 
assessment 
A I A U U Id Id 
Ischaemic aetiology 
assessment 
Ad A A Id A U U 
CRT planning A Id A U U U U 
LVAD planning A I Ad U Id U Id 
 
  Abbreviations: see above 
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Table 4: Appropriateness criteria for the use of CVI in HF follow-up clinical indications 
Clinical indications 
Cardiovascular imaging modalities 
Echo 
Stress 
Echo 
CMR RNA SPECT CT PET 
Planned     
follow-up 
HF follow-up 
Routine assessment A I U Id Id I I 
Further assessment 
as a result of 
findings in the initial 
routine assessment 
A Ad A Id U U U 
CRT follow-up A I I Id I Id I 
New symptoms   
Initial assessment A Id U I Id Id I 
Further assessment as a result of findings in 
the initial assessment 
A Ad A U U U U 
 
Abbreviations: see above
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 Table 5: Appropriateness criteria for the use of CVI in HF per clinical scenarios 
Clinical scenarios 
Cardiovascular imaging modalities 
Echo 
Stress 
Echo 
CMR RNA SPECT CT PET 
Diagnosis A A A U A A A 
Treatment planning A A A U A Ad A 
Follow-up A Ad A U U U U 
 
Abbreviations: see above 
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Appendix 
Expert Panel: Madalina Garbi, Theresa McDonagh, Bernard Cosyns, Chiara Bucciarelli-Ducci, Thor Edvardsen, 
Anastasia Kitsiou, Koen Nieman, Patrizio Lancellotti 
Voting Panel: George Athanasopoulos (Greece), Havard Dalen (Norway), Jose Juan Gomez De Diego (Spain), 
Andreas Hagendorff (Germany), Jadranka Separovic Hanzevacki (Croatia), Richard Isnard (France), Piotr Jankowski 
(Poland), Guy Lloyd (UK), Simon Matskeplishvili (Russia), Kim Munk (Denmark), Bernard Paelinck (Belgium), András 
Temesvari (Hungary), Pierluigi Temporelli (Italy), Marisa Trabulo (Portugal), Maureen Van der Vlugt (Netherlands), 
Xavier Jeanrenaud Xavier (Switzerland), Kyriakos Yiangou (Cyprus) 
Appropriateness Criteria Development Team: Madalina Garbi, Thor Edvardsen, Amit Kaura, Ameet Bakhai, Camille 
Granier-Brunello, Patrizio Lancellotti  
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